Additionally, no discernible differences in drug survival probability were observed when stratified by type of anti-TNF, type of IBD, use of immunomodulator, HLA DQA1*05 status, or prior biologic use, as depicted in Figure 2. Here, HLA-DQA2 is linked to inflammatory bowel disease.